Anuh Pharma Limited has informed the Exchange regarding 'Anuh Pharma Limited has informed the Exchange regarding intimation for re-appointment of directors retiring by rotation'.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma reported FY2025-26 revenue of Rs. 7,717 lakh (up 16.6% from Rs. 6,615 lakh in prior year) and PAT of Rs. 410 lakh (up 9.2% from Rs. 474 lakh). EBITDA margin compressed to 8.56% from 10.64% a year earlier. The company declared a dividend of Rs. 1.50 per share (30% payout on face value Rs. 5) subject to shareholder approval at the AGM on 12th August 2026. The board re-appointed two directors (Mr. Bipin Shah and Mr. Arun Todarwal) retiring by rotation. Nine promoter group shareholders holding ~0.95% equity have sought re-classification to public category. Statutory auditors issued an unmodified opinion. Operating cash flow turned negative at Rs. 301 lakh vs Rs. 3,712 lakh in prior year, driven by a near doubling of inventory to Rs. 14,776 lakh. The company has zero borrowings. Bonus shares (1:1) were issued in July 2025.
Revenue grew solidly but margin compression and negative operating cash flow are concerns — investors should monitor working capital management. The dividend and clean audit provide support. Promoter re-classification is minor (under 1% of shares).